结核病临床诊治进展年度报告（2011年）（第二部分 结核病临床治疗)

摘要/Abstract

摘要： 抗结核新药的研究：进入21世纪以来，抗结核药物的研究取得了较大进展，遴选出了20余种化合物，其中10余种已进入了临床前及临床研究阶段。

中国防痨协会临床专业委员会. 结核病临床诊治进展年度报告（2011年）（第二部分结核病临床治疗)[J]. 中国防痨杂志, 2012, 34(7): 463-471.

Chinese Antituberculosis Association of Clinic Society. Annual report on clinical diagnosis and treatment progress of tuberculosis (2011)（Part 2 clinical treatment）[J]. Chinese Journal of Antituberculosis, 2012, 34(7): 463-471.

参考文献

［1］Mukherjee T, Boshoff H. Nitroimidazoles for the treatment of TB: past, present and future.Future Med Chem, 2011, 3(11):1427-1454.

［2］Ahmad Z, Peloquin CA, Singh RP, et al. PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother, 2011, 55(1):239-245.

［3］Diacon AH, Dawson R, Hanekom M,et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis, 2011,15(7):949-954.

［4］Thompson AM, Sutherland HS, Palmer BD, et al. Synthesis and structure-activity relationships of varied ether linker analogues of the antitubercular drug (6S)-2-nitro-6-{［4-(trifluoromethoxy)benzyl］oxy}-6,7-dihydro-5h-imidazo［2,1-b］［1,3］oxazine (PA-824). J Med Chem, 2011, 54(19): 6563-6585.

［5］Tasneen R, Li SY, Peloquin CA, et al. Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother, 2011, 55(12):5485-5492.

［6］Leach KL, Brickner SJ, Noe MC,et al. Linezolid, the first oxazolidinone antibacterial agent. Ann N Y Acad Sci, 2011, （1222）:49-54.

［7］黄海荣,于霞,姜广路,等.利奈唑胺对分枝杆菌体外抑菌作用的初步研究. 中华结核和呼吸杂志,2011, (8):575-578.

［8］Tang SJ,Zhang Q,Zheng LH,et al. Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis, 2011, 64(6):509-512.

［9］Singla R, Caminero JA, Jaiswal A, et al. Linezolid:an effective,safe and cheap drug for patients failing multidrug-resistant tuberculosistreatment in India.Eur Respir J,2012,39(4):956-962.

［10］Alffenaar JW, van der Laan T, Simons S, et al. Susceptibility of clinical Mycobacterium tuberculosis isolates to a potentially less toxic derivate of Linezolid, PNU-100480. Antimicrob Agents Chemother, 2011, 55(3):1287-1289.

［11］Wallis RS, Jakubiec W, Kumar V,et al. Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis. Antimicrob Agents Chemother, 2011, 55(2):567-574.

［12］Takiff H, Guerrero E. Current prospects for the fluoroquinolones as first-line tuberculosis therapy. Antimicrob Agents Chemother, 2011, 55(12):5421-5429.

［13］Fouad M, Gallagher JC. Moxifloxacin as an alternative or additive therapy for treatment of pulmonary tuberculosis.Ann Pharmacother, 2011, 45(11):1439-1444.

［14］桂徐蔚,肖和平,胡忠义,等.氯法齐明对不同耐药类型结核分枝杆菌的体外抑菌活性研究.中华结核和呼吸杂志, 2011,34(8): 579-581.

［15］Lu Y, Zheng M, Wang B, et al. Clofazimine analogs with efficacy against experimental tuberculosis and reduced potential for accumulation.Antimicrob Agents Chemother, 2011, 55(11):5185-5193.

［16］Singh V, Mani I, Chaudhary DK, et al. The β-ketoacyl-ACP synthase from Mycobacterium tuberculosis as potential drug targets. Curr Med Chem,2011,18(9):1318-1324.

［17］Saidemberg DM, Passarelli AW, Rodrigues AV, et al. Shikimate kinase (EC 2.7.1.71) from Mycobacterium tuberculosis: kinetics and structural dynamics of a potential molecular target for drug development. Curr Med Chem,2011,18(9):1299-1310.

［18］Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits trans-translation in Mycobacterium tuberculosis. Science, 2011, 333(6049): 1630-1632.

［19］Yang XY,Chen QF,Li YP,et al.Mycobacterium vaccae as adjuvant therapy to anti-tuberculosis chemotherapy in never-treated tuberculosis patients: a meta-analysis. PLoS One, 2011,6(9):e23826.

［20］Dlugovitzky D, Stanford C, Stanford J. Immunological basis for the introduction of immunotherapy with Mycobacterium vaccae into the routine treatment of TB. Immunotherapy, 2011,3(4):557-568.

［21］Gao XF, Yang ZW, Li J. Adjunctive therapy with interferon-gamma for the treatment of pulmonary tuberculosis: a systematic review. Int J Infect Dis, 2011，15(9):e594-600.

［22］Scriba TJ, Tameris M, Mansoor N,et al. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.J Infect Dis, 2011,203(12):1832-1843.

［23］Butov DA, Pashkov YN, Stepanenko AL, et al. Phase IIb randomized trial of adjunct immunotherapy in patients with first-diagnosed tuberculosis, relapsed and multi-drug-resistant (MDR) TB. J Immune Based Ther Vaccines, 2011,9:3.

［24］Arjanova OV, Prihoda ND, Yurchenko LV, et al. Adjunct oral immunotherapy in patients with re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy, 2011,3(2):181-191.

［25］Sheikh JA, Khuller GK, Verma I. Immunotherapeutic role of Ag85B as an adjunct to antituberculous chemotherapy. J Immune Based Ther Vaccines, 2011,9:4.

［26］Faujdar J, Gupta P, Natrajan M,et al. Mycobacterium indicus pranii as stand-alone or adjunct immunotherapeutic in treatment of experimental animal tuberculosis. Indian J Med Res,2011,134(5):696-703.

［27］Ma Y, Chen HD, Wang Y, et al. Interleukin 24 as a novel potential cytokine immunotherapy for the treatment of Mycobacterium tuberculosis infection. Microbes Infect, 2011,13(12/13):1099-1100.

［28］Rosas-Taraco AG, Higgins DM, Sánchez-Campillo J,et al. Local pulmonary immunotherapy with siRNA targeting TGFβ1 enhances antimicrobial capacity in Mycobacterium tuberculosis infected mice.Tuberculosis (Edinb), 2011,91(1):98-106.

［29］Okada M, Kita Y, Nakajima T, et al. A novel therapeutic and prophylactic vaccine against tuberculosis using the cynomolgus monkey model and mouse model. Procedia Vaccinol, 2011,（4）:42-49.

［30］Kita Y, Okada M, Nakajima T,et al. Development of therapeutic and prophylactic vaccine against Tuberculosis using monkey and transgenic mice models. Hum Vaccin, 2011,7 Suppl:108-114.

［31］Okada M, Kita Y, Nakajima T,et al.Novel therapeutic vaccine: granulysin and new DNA vaccine against Tuberculosis. Hum Vaccin, 2011, 7 Suppl:60-67.

［32］Okada M, Kita Y, Nakajima T, et al. Novel prophylactic vaccine using a prime-boost method and hemagglutinating virus of Japan-envelope against tuberculosis. Clin Dev Immunol, 2011:549281.

［33］Van Dissel JT, Soonawala D, Joosten SA,et al.Ag85B-ESAT-6 adjuvanted with IC31? promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in volunteers with previous BCG vaccination or tuberculosis infection. Vaccine, 2011,29(11):2100-2109.

［34］Aagaard C, Hoang T, Dietrich J,et al.A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat Med, 2011,17(2): 189-194.

［35］Yuan W, Dong N, Zhang L,et al. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine expressing a fusion protein of Ag85B-Esat6-HspX in mice. Vaccine, 2011,30(14):2490-2497.

［36］Li Q, Yu H, Zhang Y, et al. Immunogenicity and protective efficacy of a fusion protein vaccine consisting of antigen Ag85B and HspX against Mycobacterium tuberculosis infection in mice. Scand J Immunol，2011，73(6): 568-576.

［37］Niu H,Hu L,Li Q,et al.Construction and evaluation of a multistage Mycobacterium tuberculosis subunit vaccine candidate Mtb10.4-HspX. Vaccine, 2011, 29(51):9451-9458.

［38］Desel C, Dorhoi A, Bandermann S,et al. Recombinant BCG ΔureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis, 2011, 204(10):1573-1584.

［39］Ansari MA, Zubair S, Mahmood A,et al. RD antigen based nanovaccine imparts long term protection by inducing memory response against experimental murine tuberculosis. PLoS One, 2011,6(8):e22889.

［40］梁爱军.纤支镜下局部注药治疗复治肺结核疗效观察.中国误诊学杂志,2011, 11(1): 99-100.

［41］林霏申,陈珊珊,于俊,等.纤维支气管镜下钳夹加注药治疗支气管结核223例疗效观察.临床肺科杂志, 2011, 16(8): 1219-1221.

［42］杜荣辉, 曹探赜, 连展,等. CT引导下空洞内注药在耐多药肺结核患者治疗中的作用. 临床内科杂志, 2011, 28(7): 1324-1326.

［43］吕康言, 刘桑, 岳静. 经皮肺穿刺空洞内置管注药治疗耐多药空洞肺结核疗效观察. 临床肺科杂志, 2011, 16(10): 1550-1551.

［44］王鹏,马秋野,钟殿海. 经纤维支气管镜腔内注药治疗难治性肺结核. 中国实用医刊,2011,38(10):76.

［45］张杰,王娟,王婷.良性瘢痕增生性气道狭窄经气管镜介入治疗方法的初步研究. 中华结核和呼吸杂志,2011,34（5）: 334-338.

［46］傅瑜.重视支气管结核的综合及介入治疗.中华结核和呼吸杂志,2011,34（5）: 325-326.

［47］Lee SH, Choi WJ, Sung SW,et al.Endoscopic cryotherapy of lung and bronchial tumors: a systematic review. Korean J Intern Med, 2011, 26(2): 137-144.

［48］陈志, 张广宇, 梁建琴,等. 氩等离子体凝固和冷冻序贯治疗支气管结核. 中国防痨杂志, 2011, 33(2): 213-215.

［49］Mu D, Nan D, Li W, et al.Efficacy and safety of bronchoscopic cryotherapy for granular endobronchial tuberculosis. Respiration, 2011, 82(3): 268-272.

［50］李奕,姚小鹏,白冲,等. 结核性主支气管重度狭窄合并单侧肺不张患者支气管镜介入治疗效果分析. 中华结核和呼吸杂志,2011,34(6):454-458.

［51］刘伟,傅恩清,谢永宏,等. 气管镜介入治疗支气管内膜结核方法的探讨. 中华肺部疾病杂志（电子版）,2011,4(3):183-186.

［52］方勇,沙巍. 气管镜下高压球囊扩张术治疗结核性气管狭窄一例并文献复习. 中华临床医师杂志（电子版）,2011,5(10):3084-3087.

［53］Soares Pires F, Teixeira N, Coelho F,et al. Hemoptysis—etiology, evaluation and treatment in a university hospital. Rev Port Pneumol, 2011, 17(1): 7-14.

［54］Pierce G, Ahuja C, Chadha M. Case report: Complex internal mammary to pulmonary artery fistula as a cause of hemoptysis in tuberculosis: Diagnosis and endovascular management using ethylene vinyl alcohol copolymer (Onyx). Indian J Radiol Imaging, 2011, 21(1): 10-12.

［55］Yoo DH, Yoon CJ, Kang SG, et,al. Bronchial and nonbronchial systemic artery embolization in patients with major hemoptysis: safety and efficacy of N-butyl cyanoacrylate. AJR Am J Roentgenol, 2011, 196(2): W199-204.

［56］Karmakar S, Nath A, Neyaz Z, et al.Bronchial artery aneurysm due to pulmonary tuberculosis: detection with multidetector computed tomographic angiography. J Clin Imaging Sci, 2011, 1: 26.

［57］陆文彬,刘霆,孙松,等.支气管动脉栓塞治疗大咯血的临床应用. 影像诊断与介入放射学,2011,20(2):128-129.

［58］Marchetti GP, Pinelli V, Tassi GF. 100 years of thoracoscopy: historical notes. Respiration, 2011, 82(2): 187-192.

［59］Lü G, Wang B, Li J, et,al. Anterior debridement and reconstruction via thoracoscopy-assisted mini-open approach for the treatment of thoracic spinal tuberculosis: minimum 5-year follow-up. Eur Spine J, 2012, 21(3): 463-469.

［60］Peng J,Deng X,He F,et al.Role of ventriculoperitoneal shunt surgery in grade IV tubercular meningitis with hydrocephalus. Childs Nerv Syst,2012,28(2):209-215.

［61］Ambekar S, Dwarakanath S, Chandramouli BA, et al. Does CSF composition predict shunt malfunction in tuberculous meningitis. Indian J Tuberc, 2011, 58(2): 77-81.

［62］Sarkar S,Suresh MR.An overview of tuberculosis chemotherapy:a literature review.J Pharm Pharm Sci,2011,14(2):148-161.

［63］Arjanova OV,Prihoda ND,Yurchenko LV, et al. Adjunct oral immunotherapy in patientswith re-treated, multidrug-resistant or HIV-coinfected TB. Immunotherapy，2011,3(2):181-191.

［64］WHO.Towards universal access to diagnosis and treatment of multidrug-resistant and extensively drug-resistant tuberculosis by 2015: WHO progress report 2011. Geneva:WHO,2011.

［65］Pinto L, Menzies D. Treatment of drug-resistant tuberculosis. Infect Drug Resist, 2011, 4:129-135.

［66］WHO. Guidelines for the programmatic management of drug-resistant tuberculosis 2011 update. Geneva:WHO,2011.

［67］Joseph P, Desai VB, Mohan NS, et al. Outcome of standar-dized treatment for patients with MDR-TB from Tamil Nadu, India. Indian J Med Res, 2011,133: 529-534.

［68］Udwadia ZF,Sen T,Pinto LM. Pinto. Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB. Recent Pat Antiinfect Drug Discov, 2011, 6(2), 88-91.

［69］Abbate E, Vescovo M, Natiello M, et al. Successful alternative treatment of extensively drug-resistant tuberculosis in Argentina with a combination of linezolid, moxifloxacin and thioridazine. J Antimicrob Chemother, 2012,67(2):473-477.

［70］Tangg SJ,Zhang Q,Zheng LH,et al. Efficacy and safety of linezolid in the treatment of extensively drug-resistant tuberculosis. Jpn J Infect Dis, 2011,64(6):509-512.

［71］Jacobson KR,Theron D,Victor TC,et al.Treatment outcomes of isoniazid-resistant tuberculosis patients, Western Cape Province, South Africa. Clin Infect Dis, 2011,53(4):369-372.

［72］Lee J,Lee CH,Kim DK,et al. Retrospective comparison of levofloxacin and moxifloxacin on multidrug-resistant tuberculosis treatment outcomes. Korean J Intern Med, 2011, 26(2):153-159.

［73］Bonnet M,Pardini M,Meacci F,et al. Treatment of tuberculosis in a region with high drug resistance: outcomes, drug resistance amplification and re-infection. PLoS One, 2011,6(8):e23081.

［74］Farley JE,Ram M,Pan W,et al.Outcomes of multi-drug resistant tuberculosis (MDR-TB) among a cohort of South African patients with high HIV prevalence. PLoS One, 2011,6(7):e20436

［75］Isaakidis P,Cox HS,Varghese B,et al. Ambulatory multi-drug resistant tuberculosis treatment outcomes in a cohort of HIV-infected patients in a slum setting in Mumbai, India. PLoS One, 2011,6(12):e28066.

［76］Yaldiz S,Gursoy S,Ucvet A,et al. Surgery offers high cure rates in multidrug-resistant tuberculosis. Ann Thorac Cardiovasc Surg,2011,17(2): 143-147.

［77］Qazi F, Khan U, Khowaja S,et al. Predictors of delayed culture conversion in patients treated for multidrug-resistant tuberculosis in Pakistan. Int J Tuberc Lung Dis, 2011,15(11):1556-1559, i.

［78］Kurbatova EV, Gammino VM, Bayona J,et al. Frequency and type of microbiological monitoring of multidrug-resistant tuberculosis treatment. Int J Tuberc Lung Dis, 2011,15(11):1553-1555,i.

［79］Smith JP. Nanoparticle delivery of anti-tuberculosis chemotherapy as a potential mediator against drug-resistant tuberculosis. Yale J Biol Med,2011,84(4):361-369.

［80］Kumar G, Malhotra S, Shafiq N,et al. In vitro physicochemical characterization and short term in vivo tolerability study of ethionamide loaded PLGA nanoparticles: potentially effective agent for multidrug resistant tuberculosis. J Microencapsul,2011,28(8):717-728.

［81］Ianghammer B，Inci I，Weder W. Impact of surgical intervention in the treatment of pulmonary tuberculosis.Ther Umsch,2011,68(7):407-410.

［82］周逸鸣,姜格宁,丁嘉安.耐多药肺结核的外科治疗.中华结核和呼吸杂志,2011,34（8）:614-615.

［83］Xu HB,Jiang RH,Li L.Pulmonary resection for patients with multidrugresistant tuberculosis: systematic review and meta-analysis.J Antimicrob Chemother,2011,66(8): 1687-1695.

［84］Adhvaryu M,Vakharia B.Drug-resistant tuberculosis:emerging treatment options.Clin Pharmacol,2011,3: 51-67.

［85］Safwat TM,Elmasry AA,Mohamed AKM. Prevalence of multi-drug resistant tuberculosis in Abbassia Chest Hospital from July 2006 to December 2009. Egyptian J Bronchol,2011,5（2）:124-130.

［86］Yaldiz S,Gursoy S, Ucvet A,et al. Surgery offers high cure rates in multidrug-resistant tuberculosis.Ann Thorac Cardiovasc Surg, 2011, 17（2）:143-147.

［87］Yerimbetov K,Abildaev T,Alenova A,et al. The experience of surgical treatment of patients with pulmonary extensivel resistant tuberculosis.MHSJ,2011,5(1): 84-87.

［88］Brik A,Salem AM,Shoukry A,et al. Surgery for hemoptysis in various pulmonary tuberculous lesions:a prospective study. Interact Cardiovasc Thorac Surg,2011,13(3):276-279.

［89］Nakajima Y.The role and landscape of surgical treatment for mycobacteriosis.Kekkaku,2011,86（12）:911-915.

［90］Lejay A, Falcoz PE, Santelmo N,et al.Surgery for asperrgilloma：time trend towards improved results? Interact Cardiovasc Thorac Surg,2011,13(4):392-395.

［91］Garg RK,Somvanshi DS. Spinal tuberculosis: a review. J Spinal Cord Med, 2011,34(5):440-454.

［92］廖俊君.脊柱结核内固定治疗进展.医学综述,2011,17（13）:1995-1997.

［93］洪征,白连启,阎东杰,等.肺结核全肺切除近期并发症的治疗.中华结核和呼吸杂志,2011,34（8）:582-585.

［94］葛棣,卢春来,冯自豪,等.肺切除术后支气管胸膜瘘的治疗.中华结核和呼吸杂志,2011,34（3）:225-227.

［95］常宽.结核性脓胸的外科治疗现状.新疆医科大学学报,2011,34（2）:216-219.

［96］Thomas MO,Ogunleye EO. Chronic empyema: aetiopathology and management challenges in the developing world. Surgical Science, 2011,(2):446-450.

［97］徐澄澄,付向宁.带蒂大网膜移植在难治性胸壁结核外科治疗中的应用.临床外科杂志,2011,19（6）:411-413.

［98］詹锋,姜镭裘,华德生.负压封闭引流术治疗胸壁结核临床研究.中华实验外科杂志,2011,28（3）:461.

［99］Tassi GF, Marchetti GP, Aliprandi PL.Advanced medical thoracoscopy. Monaldi Arch Chest Dis, 2011,75(1):99-101.

［100］姜永光,赵佳晖,侯铸,等.经阴道辅助腹腔镜肾切除术治疗结核无功能肾1例.临床泌尿外科杂志,2011,26（8）:616.